CGTLive’s Weekly Rewind – July 15, 2022

Article

Review top news and interview highlights from the week ending July 15, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. ATA188 Shows No Significant Improvements in MS, Study to Continue

There were not enough data at 6 months to predict expanded disability status scale (EDSS) improvements after treatment.

2. First Patient With Mesial Temporal Lobe Epilepsy Dosed With Neural Cell Therapy

Patient recruitment for the clinical trial is currently underway at epilepsy centers throughout the US.

3. First Patient With Familial Hypercholesteremia Dosed With Base-Editing Therapy

Verve Therapeutics is currently conducting a clinical trial in New Zealand and expects to be able to open trials in the UK and US later in 2022.

4. TCR T Cell Therapy for HBV-Related Liver Cancer Cleared for US Trial

SCG101 will be evaluated in trials across China, Singapore, and the US.

5. Legend Biotech Drops Lymphoma CAR T-Cell Therapy

Legend Biotech seeks to prioritize other product candidates in its pipeline.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.